Product Description
HLX-1502 was discovered by Healx’s proprietary AI drug discovery platform, and has a first in class mechanism for the treatment of Neurofibromatosis Type 1. Healx aims to develop HLX-1502 for both plexiform and cutaneous subtypes of NF1, thus enabling access to treatment for a wide range of NF1 patients. Healx plans to submit an Investigational New Drug (IND) application to take its wholly-owned HLX-1502 program into clinical trials in 2024. (Sourced from: https://healx.ai/healx-receives-us-orphan-drug-designation-for-its-ai-discovered-treatment-of-neurofibromatosis-type-1/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Healx
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|